Clear all

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

809 results found

Analysis PRO In-house
Ask Lexy

Lexology PRO | European Union, Italy, Netherlands, etc. | 19 Jul 2021

Dutch enforcer issues first excessive pricing fine

The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
Analysis PRO In-house
Ask Lexy

Lexology PRO | United Kingdom | 15 Jul 2021

UK hits pharma companies with £266 million fines for overcharging health service

The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.
Analysis PRO In-house
Ask Lexy

PRO Compliance | USA | 11 Jun 2020

States file third suit against generics industry

A coalition of 51 US states and territories have filed their third sweeping antitrust lawsuit against the generic pharmaceuticals industry, alleging a massive conspiracy to fix prices for topical skin treatments.
Article
Ask Lexy

AA Thornton | United Kingdom | 20 Nov 2018

Landmark UK Supreme Court Judgment in Warner Lambert v Generics (Mylan) & Actavis (Pregabalin/Lyrica)

The Supreme Court of the United Kingdom has now released their long-awaited decision relating to the tests for sufficiency and infringement for second…
Article
Ask Lexy

Freshfields Bruckhaus Deringer | European Union, United Kingdom | 14 Nov 2018

UK Supreme Court patent decision in Lyrica: What you need to know

The UK Supreme Court handed down its much anticipated judgment in the Warner-Lambert v Mylan and Actavis (Lyrica) case today (https://www…
Article
Ask Lexy

Knobbe Martens | USA | 11 Sep 2018

Orexo AB, Orexo US INC., v Actavis Elizabeth LLC

Objective indicia of nonobviousness cannot be dismissed merely because all the ingredients in a formulation were generally known and nothing prevented…
Article
Ask Lexy

Rothwell, Figg, Ernst & Manbeck, PC | USA | 7 Aug 2018

Using Theses as Prior Art at the PTAB

Based on recent Patent Trial and Appeal Board (“PTAB” or “the Board”) decisions, the best practice to establish an academic thesis as a printed…
Article
Ask Lexy

Boult Wade Tennant LLP | United Kingdom, USA | 3 Jul 2018

Innovation key to driving success in healthcare

As the NHS turns 70, it is notable that the focus for the future is on innovation for the improvement of patient care. Technologies spanning genetic…
Article
Ask Lexy

Baker McKenzie | Singapore | 30 Apr 2018

Purposive approach to patent claim construction and counterclaims for groundless threats - Lee Tat Cheng v Maka GPS Technologies Pte Ltd [2018] SGCA 18

Lee Tat Cheng (the "Appellant") is the proprietor of a patent in respect of an inautomotive accident recordal system. In the High Court in Lee Tat…
Article
Ask Lexy

Ladas & Parry LLP | United Kingdom | 19 Mar 2018

UK SUPREME COURT DECISION IN ACTAVIS v. ELI LILLY - DOCTRINE OF EQUIVALENTS RECOGNIZED

In its decision of July 12, 2017 in Actavis v. Eli Lilly, the Supreme Court of the United Kingdom for the first time formally adopted the…
Previous page 1 2 3 ...